Prevalence of Seizure In PKU: An Analytic Historical Study by KARIMZADEH, Parvaneh et al.
15Iran J Child Neurology   Vol4 No2 Sep  2010
1. Associate Professor of 
Pediatric Neurology, Shahid 
Beheshti University of Medical 
Sciences (SBMU), Pediatric 
Neurology Research Center, 
Tehran, Iran
2. Assistant Professor of 
Pediatric Endocrinology, Shahid 
Beheshti University of Medical 
Sciences (SBMU), Pediatric 
Neurology  Research Center, 
Tehran, Iran
3. Resident of Pediatrics, Shahid 
Beheshti University of Medical 
Sciences (SBMU), Pediatric 




Karimzadeh P. MD 
Pediatric Neurology Research  
Center,Mofid Children Hospital, 
Tehran, Iran
Tel: +98 21 22909559
Email:Pkarimzadeh@sbmu.ac.ir
PREVALENCE OF SEIZURE IN PKU: 
AN ANALYTIC HISTORICAL STUDY
Abstract
Objective
Phenylketonuria (PKU) is an autosomal recessive metabolic genetic disorder 
characterized by a deficiency in the hepatic enzyme phenylalanine hydroxylase 
(PAH) which can cause problems with brain development, leading to progressive 
mental retardation, brain damage, and seizures. In this study we evaluated the 
frequency of seizure, EEG abnormality and behavioral disorders.
Materials & Methods
In this case study, 94 PKU children aged between 1 month and 23 years who 
were referred to Mofid children Hospital between 2009 and 2010 were enrolled. 
Patients were age and sex matched. Statistical tests were used for comparing 
patients’ data.
Results 
The mean age of patients was 8.4 years. Parents were relatives in 80.9% of the 
cases (76 patients). Of all, 43% (45 patients) had seizure but EEG was abnormal 
only in 81% of them (35 patients out of 43 patients). Totally, EEG was abnormal 
in 67% of the cases (63 patients) of whom 44.4% (28 patients of 63 patients) 
did not have seizure. Therefore, there was a significant relationship between 
seizure and EEG abnormality. The phenylalanine level ranged from 8mg/dL 
to 50mg/dL (mean: 18.88 mg/dL) at the time of diagnosis and from 0.4mg/dL 
to 18mg/dL (mean: 7.37mg/dL) at the time of evaluation. On the other hand, 
we observed abnormal behaviors in all EEG abnormalities and there was a 
significant relationship between EEG abnormality and behavioral disorders.
Conclusion
In our study, the prevalence of seizure was less than EEG abnormality and 
there was a significant relationship between EEG abnormalities and behavioral 
disorders in patients with Phenylketonuria regardless of seizure.The authors 
believe that treatment of EEG abnormalities may lead to the correction of 
behavioral disorders in these patients. 
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Introduction
Phenylketonuria (PKU) is an autosomal recessive metabolic genetic disorder 
characterized by a deficiency in the hepatic enzyme phenylalanine hydroxylase (PAH) 
(1). This enzyme is necessary to metabolize the amino acid phenylalanine (‘Phe’) to 
the amino acid  tyrosine. When PAH is deficient, phenylalanine accumulates and 
is converted into phenylpyruvate (also known as phenylketone), which is detected 
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in the urine (2). PKU (OMIM 261600) and its milder 
variant HPA are genetic disorders characterized by a 
deficiency in PAH (EC 1.14.16.1), an enzyme that is 
required to metabolize l-Phe to l-Tyrosine (l-Tyr). On the 
basis of blood Phe concentrations, PAH deficiency can 
be classified into classic PKU (Phe >1200 μmol/L), mild 
PKU (Phe = 600 1200 μmol/L) and mild HPA, where 
blood Phe is elevated above upper reference limit, but 
below 600 μmol/L (3).
The decreased PAH activity found in most forms of 
PKU and HPA are caused by mutations in the PAH gene, 
resulting in a non-functional PAH enzyme. Untreated 
PKU is associated with an abnormal phenotype including 
growth failure, microcephaly, seizures and intellectual 
impairment caused by the accumulation of toxic by-
products of Phe metabolism. The incidence of PKU 
or HPA is highest amongst Caucasians, occurring in 
approximately 1 in 10,000 births. PKU can be detected 
in newborn screening tests as performed in most 
Western countries (4). Moreover, decreased or absent 
PAH activity can lead to the deficiency of Tyr and its 
downstream products, including melanin, l-thyroxine 
and the catecholamine neurotransmitters (5). 
Serum phenylalanine concentrations in infants with 
PKU are normal at birth but begin to rise within the first 
few weeks of life. Excessive phenylalanine is generally 
thought to be responsible for the brain damage that 
underlies the severe mental retardation and seizure 
disorder of PKU. In untreated infants, cognitive delay 
becomes evident within 6 months and is progressive. 
The majority of affected children are unable to talk, and a 
significant proportion never learn to walk. Characteristic 
physical findings include light-colored hair and eye, skin 
pigmentation, an eczematous rash, hyperactive behavior 
and a musty or mousy odor (due to phenylacetic acid in 
the sweat).
Approximately 25% of the patients have generalized 
or partial seizures. Infantile spasms and myoclonic 
seizures may occur. On EEG, all patients have slowing 
epileptiform discharges or hypsarrhythmic patterns (6). 
The foundation of PKU treatment is a low Phe diet 
which, by reducing or normalizing Phe concentrations, 
prevents the development of the neurological and 
psychological changes. Since neurological changes 
have been demonstrated within one month of birth, it is 
recommended that dietary restriction should be started 
early and be continued through childhood when neural 
development is maximal (7). Clinical neurological 
abnormalities, affected neuropsychological performance 
and brain imaging in adults with PKU has led to a 
consensus that the PKU diet should be followed for life 
(8, 9).
Magnetic Resonance Imaging (MRI) shows white matter 
lesions in the brain of adult PKU patients and their size and 
number directly correlate with blood Phe concentration 
(10). Such changes can be reversed by lowering blood 
Phe levels (11,12). Accordingly, Phe treatment targets 
have been established (birth to 8 years: Phe 100–350 
μmol/L, older children and adults: Phe <700 μmol/L). 
(13,14)
Materials & Methods
In this case study, conducted between 2009 and 2010, 
94 PKU patients (45 male, 49 female) with a mean age 
of 8.49±6.24 years who were referred to Mofid Children 
Hospital, Tehran, were evaluated. 
These patients were diagnosed either by newborn 
screening tests or later in life and were followed at Mofid 
Children Hospital. The diagnosis of PKU was made if 
serum phenylalanine concentration was above 6 mg/dl in 
untreated newborns (15). The patients were sex and age 
matched.
we reviewed of all medical records  and past history of 
patients to revealed  seizures. 94  PKU patients (45males, 
49 females) constituted the study subject in this report. 
The age at onset of PKU ranged vastly from 1 month to 
23 years. The diagnosis of PKU was made on the basis 
of serum phenylalanine (PHE) level more than 1200 
mmol/L, clinical manifestations and urine Pterin analysis 
excluding atypical PKU. An informed written consent 
was obtained from parents or legal guardians. Age, sex 
and family history findings were recorded for all cases. 
A pediatric neurologist took the history of seizure in all 
cases and recorded positive findings, so all patients who 
recently had seizures were excluded. Blood samples were 
collected from all participants for the measurement of 
serum phenylalanine. All patients were referred for EEG 
recording after sleep deprivation for 8-12 hours.
DSMA IV was used to detect behavioral disturbances 
in all cases. Finally, statistical tests were applied for 
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comparing data patients’ data and a P value less than 0.05 
was considered significant. 
Results
We studied 94 children (45 male, 49 female), with 
PKU. The mean age of the patients was 8.49 ± 6.24 
years. Parents were relatives in 80.9% of the cases (76 
patients). Of all, 43% (45 patients) had seizures and 47% 
(51 patients) were seizure free. Of cases with seizure, 20 
(46%) were male and 23 (54%) were female (Table 1). 
In patients with clinical seizure, EEG was abnormal in 
81% (35 patients out of 43 patients with seizure) and 
normal in 19% (8 patients out of 43 patients with seizure); 
so, there was a significant relationship between clinical 
seizure and EEG abnormality (P<0.001) (Table 2).
EEG was abnormal in 67% of the cases (63 patients) while 
the remaining 31 patients (37%) had a normal EEG. In 
patients with an abnormal EEG, 44.4% (28 patients out 
of 63 patients) had no clinical seizure.
In patients with EEG abnormality, 34 (53%) had 
mild, 9 (14%) had moderate and 20 (33%) had severe 
abnormalities. Fifteen patients (44%) with a mild EEG 
abnormality and 12 patients (60%) with a severe EEG 
abnormality had clinical seizures. We found a significant 
relationship between clinical seizures and the severity of 
EEG abnormalities (P<0.001) (Table 3).
The frequency of  behavioral disturbances was 73 (77.7%) 
in our patients and there was a significant relationship 
between  behavioral disturbances and EEG abnormality 
(P<0.001).
 Phenylalanine level ranged between 8 mg/dL and 50 mg/
dL (mean: 18.88 mg/dL ±7.76) at the time of diagnosis 
and between 0.4 mg/dL and 18 mg/dL (mean: 7.37mg/dL 
± 4.84) at the time of evaluation. 
There was no significant relationship  between clinical 
seizure and phenylalanine level.







female 26 23 49
male 25 20 45
Total 51 43 94
Table 2. Correlation between EEG and seizure in patients
 




ABNORMAL 28 35 63
NORMAL 23 8 31
Total 51 43 94
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Discussion
Several neurodegenerative disorders cause seizure, 
including the following: Alzheimer’s disease, Creutzfeld-
Jakob disease, Neurofibromatosis, Phenylketonuria 
(PKU), Tuberous Sclerosis, Sturge-Weber syndrome, 
Tay-Sachs disease, etc (16).
Metabolic diseases of the nervous system vary 
considerably in their clinical and pathological aspects. 
In these disorders, mental retardation and epileptic 
syndrome are the prominent presentation. 
Pulariani studied 27 patients aged between 3 months 
and 3 years: 15 PKU cases, 4 homocystinuria cases, 1 
hyper-prolinemia patient, 5 methylmalonic academia 
cases and 2 cases of combined disorders. He found 
epileptic syndrome in 21 patients, mental retardation in 1, 
spasticity in 5 and ataxia in 1 patient. Epileptic syndrome 
manifested with generalized seizures (grand mal: 6 
cases, myoclonic absences: 13 cases) and partial seizures 
(simple motor: 2 cases). 
Investigations did not show a reliable correlation between 
certain forms of enzyme deficiency and EEG patterns. 
The best outcome was observed in the cases of PKU with 
early diagnosis (17). 
Heike Rolle-Daya et al reported the electroence 
phalographic findings of 90 patients with phenyl-
ketonuria (PKU) who were visited in one clinic. 
Seventy three percent of the patients with classical 
PKU who were diagnosed and treated early (group 
1) had normal EEGs, 23% had mild background 
abnormalities, and 4% had paroxysmal discharges. 
Only 31% of the patients in whom PKU was diagnosed 
after 6 months of age (group 2) had normal EEGs; 
however, 24% had background abnormalities and 
45% had paroxysmal discharges (18). 
To determine the importance of an abnormal EEG in 
phenylketonuria (PKU), Gross PT et al reviewed 137 
EEGs from 48 patients with PKU. Patients were divided 
into three groups: group 1 (n = 14) had only normal 
EEGs, group 2 (n = 20) had only abnormal EEGs, and 
group 3 (n= 14) had normal EEGs in the beginning which 
became abnormal later (19).
 In another study, the frequency of EEG changes was 
evaluated. This prevalence ranged from 50% to 73% in 
PKU patients.
We found EEG abnormalities in 63% that is similar to 
other studies. 
Ghada M.H reviewed 60 cases with classic PKU of whom 
21 cases (35%) had epilepsy. In that study, epilepsy was 
more prevalent in males than females (66.7% versus 
33.3%) and 69.2% (27/39) of PKU patients who had no 
history of epilepsy in any stage of their life had normal 
EEGs (20). In our study, 43% of the patients had seizure 
and the prevalence of clinical seizure was 46% in males 
and 54% in females which was similar to the study by 
Ghada in which the prevalence was higher in males than 
females.
Ghada et al reported that about 25% of the children had 
seizure and more than 50% had electroencephalographic 
abnormalities (20). Also, in that study, the prevalence 
of seizure and EEG abnormality was 43% and 67% 
respectively which means that some patients had EEG 
abnormalities without any clinical seizures. 
There is evidence that subclinical discharges can cause 
behavioral disorders and cognitive impairment. It seems 
that negative effects of these epileptiform discharges 
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Mild 19 15 34
Moderate 1 8 9
severe 8 12 20
Normal 23 8 31
Total 51 43 94
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on the choice reaction time, verbal and nonverbal skills 
and behavioral abilities lead to cognitive and behavioral 
disorder (21). 
Smithet al used the Rutter Behavior Questionnaire for 
patients with PKU and school teachers assessed the 
frequency of common abnormal behaviors in 544 8-
year-old children with phenylketonuria who were born 
in the United Kingdom. The diagnosis of PKU was made 
by routine testing in infancy. Patients had mannerisms, 
hyperactivity, signs of anxiety and were less responsive 
and more reclusive than controls. However, they were less 
aggressive and untruthful, more obedient, and not absent 
from school more frequently. The increased frequency of 
deviant behavior may be the result of both psychologic 
stress and neurologic impairment (22).
In our study, 76% of the patients had a pattern of 
behavior disturbance such as anxiety, hyperactivity 
and aggressiveness. These behavioral disorders were in 
accordance with their EEG abnormalities.
In conclusion, In our study, the prevalence of seizure 
was less than EEG abnormality. It means that some 
patients had EEG abnormalities without clinical seizure. 
Most patients who had seizure had abnormal EEGs, 
too. There was a significant correlation between EEG 
abnormalities and behavioral disorders in patients with 
Phenylketonuria regardless of seizure.
The authors believe that treatment of EEG abnormalities 
may lead to the correction of  behavioral disorders in 
these patients. 
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